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ABSTRACT
BACKGROUND  OBJECTIVES
To compare the efficacy of  Tramadol, Nalbuphine, and Clonidine in the
treatment of shivering after spinal anaesthesia in caesarean section .
METHODS:
A prospective randomised comparative study was conducted between
1.8.2013 to 1.9.2014 to compare the efficacy of Tramadol, Nalbuphine, Clonidine
in treatment of shivering after spinal anaesthesia in casearean section. Patients
included in this study are those who developed shivering after spinal anaesthesia
for caesarean section.
Patients were randomly allotted to one of the three groups, namely T group
(25) who received Tramadol 0.5mg/kg i.v., N group (25) who received Nalbuphine
0.1mg/kg i.v  and C group (25)who received clonidine 0.5µg/kg iv.
Vital parameters of the patient such as H.R. B.P. SPO2, RR and temperature
were monitored at regular intervals as per protocol. Events such as onset of
shivering, time taken to stop shivering, recurrence of shivering and side effects like
nausea, vomiting  bradycardia, hypotension and sedation were also noted.
Statistical tests like chi square test, Anova test were applied to the data
collected.
Results:
Among the 75 patients who developed shivering of grades 3 & 4  requiring
treatment were randomly allotted to one of the three  group.
The mean temperature at which patient developed shivering was 36.4C, and
the mean duration of shivering to occur following spinal anaesthesia was 22.5 mts.
Tramadol 0.5 mg/kg controlled shivering in mean time of 4 minutes,
clonidine 0.5 µg/kg, controlled shivering in mean time of   2 minutes and
Nalbuphine 0.1 mg/kg controlled shivering in mean time of  4 minutes .
Conclusion :-
Our study concludes that  all three drugs namely  Tramadol clonidine  and
nalbuphine were effective in controlling postspinal anesthesia  shivering . among
them clonidine took lesser time to achieve complete  cessation of shivering and
also maintained better hemodynamics throughout the study.
Key words:-
Shivering, Spinal anaesthesia, Nalbuphine, Tramadol, clonidine.
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INTRODUCTION 
 
Regional anesthesia (spinal anaesthesia)  is a safe and commonly 
performed technique for Caesarean section due to its quick onset, dense 
blockade, low dose local anaesthetic usage in both elective and emergency 
caesarean section. The incidence of shivering after spinal anaesthesia for 
caesarean section is about 40 -50% which is an unpleasant and 
physiologically stressful condition for the patient.  
 
Shivering  is a  defense mechanism in response to early hypothermia 
in warm blooded animals. When the core temperature drops, the shivering 
reflex is triggered to maintain homeostasis. Shivering is a serious 
complication leading to increased metabolic rate, increased oxygen 
consumption, increased CO2 production.  It may cause  arterial hypoxemia, 
lactic acidosis, increased intraocular Pressure, increased intracranial 
pressure, increased surgical bleeding, wound infection and it interfers with 
pulse rate, blood pressure, and ECG monitoring.  It is detrimental to 
patients with low cardio respiratory reserve.  
 
Perioperative hypothermia is the primary cause for shivering which 
occurs due to neuraxial blockade induced inhibition of thermoregulatory 
centre, peripheral vasodilatation due to sympathetic blockade, cold 
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operating room and cold iv fluids .Various non pharmacological and 
pharmacological interventions are used to control post spinal anesthesia 
shivering. Non pharmacological methods includes convection warming 
system and radiant heat system which uses specialized equipments to 
control or prevent shivering which are often expensive and are not practical 
in all clinical settings. Pharmacological agents used to control shivering 
include pethidine, clonidine, tramadol, nalbuphine, ondasetron, ketanserin, 
magnesiumsulphate, propofol, alfentanil, sufentanil, physostigmine,  
doxapram,   methylphenidate,   ketamine, etc. Among them pethidine  is  
the  commonly  used  drug   to  treat  shivering, but it  has  its  own  
limitation. 
  
 So we undertook a prospective, randomized clinical study to 
compare the efficacy of tramadol, clonidine and nalbuphine in the treatment 
of  shivering  after  spinal  anaesthesia  in  caesarean patients. Tramadol  is   
a  synthetic  opioid  which  has   lesser   respiratory  depression  and  less  
sedation.  clonidine  is  a alpha2 agonist  which  has  better hemodynamics. 
Nalbuphine is a opioid agonist antagonist with ceiling effect on respiration. 
Hence these three drugs are selected for study. 
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AIM AND OBJECTIVES 
 
 The aim of  this prospective double blind   randomized clinical  study 
was to compare the efficacy, potency, hemodynamic effects, complications  
and  side effects of  clonidine, nalbuphine  and tramadol for control  of  
shivering  after  Spinal anesthesia in  caesarean  section  and  to determine  
which  of  these  pharmacological  interventions  serves  the best  to  
achieve  benefit  with  minimal  side effect.  
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REVIEW OF LITERATURE 
 
People’s journal of scientific research vol 7, Jan 2014; research 
article by S Kulshrestha, R.K. Methta, conducted RCT on efficacy of 
intravenous  clonidine  and  tramadol on  postspinal  aneasthesia  shivering 
in  elective lower segment  caesarean section.  In  this double blind study 90 
patients belonging to ASA  grade I & II between 18-35 years scheduled for 
elective LSCS under spinal anaesthesia  who developed  shivering  were  
allocated  into 2 groups, Group C and Group T, given clonidine 50µg and 
tramadol 50mg iv respectively. The mean interval  between the drug 
injection  and complete cessation of shivering  was significantly earlier  in 
group C than group T. The side effects  were less in clonidine  than  
tramadol group.  
 
Beena yousuf, et al, 2013; evaluated the efficacy of tramadol in 
preventing post-operative shivering using thiopentone and propofol as 
induction agent in  general anaesthesia. It was a randomized controlled 
trial, 124 patients under going general anaesthesia for various procedures 
who received either thiopentone  or propofol as induction agent. Each 
group subdivided to receive either tramadol or saline before wound closure.  
They observed higher incidence of post operative shivering in Thiopentone 
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group and lowest in propofol group (P<0.05) . They concluded that 
prophylactic use of tramadol in a dose of 1mg/1kg with propofol as an 
induction agent, significantly reduced the incidence of post operative  
shivering  in patients  recovering  from general anaesthesia.  
 
Ushashukla, et al., IJA 2011; conducted   a  prospective double blind 
randomized  controlled  clinical trails, to evaluate  the  efficacy, potency, 
side effects of  clonidine  and  tramadol in post spinal anaesthesia shivering. 
In that study 80 ASA I & II patients scheduled for various surgical  
procedures  under spinal anaesthesia were selected who developed 
shivering, were selected into two groups. Group C(n=40) and group 
T(n=40) given clonidine 0.5µg/kg and tramadol 0.5mg/kg iv respectively. 
Disappearance of shivering was significantly earlier in groupC  than  in  
group T  (P= 0.0000001). Nausea, vomiting, dizziness were found to  be  
higher  in  group T. 
 
 Cari A miller, Harris college, Texas, October 2011 conducted  study 
on drugs to reduce post spinal anaesthesia shivering. In  his  project, he 
compared  the drugs with  anti shivering  property, he recommended 
tramadol is equally effective to meperidine and also recommended, 
clonidine, nalbuphine and doxapram in the treatment of  post-spinal 
anaesthesia shivering. 
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Fatemeh Haji Mohammadi, et al., in 2010 conducted a double blind 
clinical trial on patients suffering from shivering following general 
anaesthesia  and compared the effectiveness of tramadol and meperidine in 
controlling post anaesthesia  shivering.  The patients received  tramadol 
1mg/kg  or 0.5mg/kg  meperidine i.v, over 30 seconds, with shivering grade 
2 or 3. Shivering  disappeared in 40% following  tramadol and 53.3%  after 
meperidine. They concluded  both  drugs were effective in reducing  
shivering  and  tramadol  is as effective as meperidine in tackling  
postanaesthetic  shivering. 
  
 
 Dhimar and colleagues in 2010, compared  meperidine and tramadol 
in the treatment of post Anaesthesia shivering  under  regional anesthesia.  
It  included  60 patients  undergoing  various surgeries in both genders with 
ASA grade I, II or III, this study found tramadol and meperidine equally 
effective and however  tramadol  stopped shivering faster  than  
meperidine. Doses  were 1mg/kg  for  both drugs. Tramadol was superior 
since the disappearance of shivering took 5mts with Tramadol  and 20mts  
in  meperidine  group.  
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Trakalthong C, Areejuathawa J, et al; in 2009: reviewed studies 
relating  the  effectiveness  of  drugs  in  controlling  shivering,  included 9 
RCTS for meperidine, 3 for Tramadol, ketanserin, Doxapram and clonidine 
and 2 for nalbuphine;  Evidence was sufficient and statistically  significant 
for these six drugs. 
 
Fatemeh,  et al, in 2009; conducted a randomized double blind study  
on  90 ASA I & II  candidates for  caesarean section. They  randomly  
allocated  two groups  (study and control). All patients undergone  spinal 
anaesthesia . At  the end  of  surgery ,1mg/kg tramadol in  20ml  normal  
saline  given  to  study  group  and 20ml  normal saline given to control 
group intravenously. Patients evaluated for hemodynamics, arterial O2 
saturation, oral temperature, presence and intensity of shivering and nausea 
and vomiting. Thirty nine patients (86.6%) in control group and (8.8%) 
only four patients in study group developed shivering. In  control group, 
thirty three  patients has moderate shivering  and  six patient  has  mild 
shivering. In  study group  two patients  has  moderate  and  two has mild 
shivering ( P < 0.001) there were no significant differences with respect to 
heart rate, systolic and diastolic blood pressure, oxygen saturation, nausea, 
vomiting and body temperature  of   the patients. They concluded   
tramadol  was effective in the prevention of post spinal anaesthesia 
shivering and the drug does not lead into any hemodynamic complications.  
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Mohta M. Kumari N. et al, in 2009; conducted a study to compare 
the effects of tramadol with pethidine for prevention of post-anesthetic 
shivering, to find the dose of tramadol that provide the dual effect  of anti 
shivering and analgesic effect; they included 165 patients allocated to 5 
groups of 33 each. Tramadol in doses of 1,2,3 mg/kg and pethidine 
0.5mg/kg  and  normal saline  were given  at  the time of wound closure. 
All  the  three  doses were effective in preventing post anaesthetic shivering 
. Tramadol 2mg/kg had the best effect of antishivering and analgesic 
efficacy, without excessive sedation.  
 
S. Atashkhoyi and S. Negargar in 2008; conducted a double blind 
study on 70 healthy obstetric patients scheduled for caesarean section under 
spinal anaesthesia.  Immediately after spinal anaesthesia, 35 patients 
received  1mg/kg tramadol  and  normal saline for 35 patients, the incidence 
of shivering was lower in patients who got Tramadol than placebo 
(28.57%) Vs (65.71% ) (P<0.001). In placebo group 26 patients (74.28%) 
had  post-operative pain compared to 4 in the study group (11.42%  
P(<0.0001), there was  no  difference  in side effects  between  the two 
groups. The  result  revealed  that  tramadol 1mg//1kg was effective in  the  
prevention  of  shivering  in  caesarean patients after spinal anaesthesia. 
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 Oranuch Kyokong et al., 2007 conducted a double blind randomised 
controlled study on  two hundred and eighty parturients were divided into 4 
groups, group T, group N, group O and , group P were given tramadol 
0.5mg/kg, nalbuphine 0.05mg/kg, Ondansetron 0.1mg/kg and normal saline 
5ml IV given respectively for controlling post anaesthesia shivering. 
Evaluated at 15mts after treatment. The success rate in controlling 
shivering were 88, 81, 61 and 36% respectively in group T,N,O,P with p 
value of  (P<0.001, 0.001, 0.003 and < 0.001 and 0.009) respectively.  
Recurrence  rate of  post anaesthesia shivering  in groups T, N, O, P were 
14% 15% 11% and 28%; p = 0.329. other side effects were few. They 
concluded that tramadol, nalbuphine, ondansetron were effective after 
intrathecal morphine in caesarean patients with low recurrence rates of 
shivering. Tramadol and nalbuphine were superior to ondansetron.  
 
 
  Vander stappen, et al;  in april 1999; conducted  a large prospective 
double  blind study  to evaluate  the effect of  prophylactic clonidine on 
post operative shivering. 280 patients of ASA I and II were selected who 
undergone elective peripheral surgery, were given either placebo or 
clonidine 2µg/kg iv, over 10 mts after induction of anaesthesia, Clonidine 
was found to reduce the severity ( P=0.005) and duration of post-op 
shivering ( p=0.01) . It did not increase  post-operative sedation and 
concluded clonidine reduces postoperative  shivering.  
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Zahedi  in 2004; conducted and published a larger RCT. This study 
was a double blind trial on patients undergoing cataract surgery under 
general anaesthesia. The  participants  were  ASA  I and  II. In  120 patients 
with  shivering  who  were  treated with  tramadol 1mg/kg and meperidine 
0.5mg/kg,  Zahedi  reported  tramadol  was  more  effective due to  faster 
onset, no recurrence of shivering, shorter  duration of  recovery and  fewer  
adverse effects. 
 
 Kranke P, et al., in 2004 conducted a study to evaluate the anti 
shivering property of certain drugs like clonidine, meperidine, ketanserin & 
doxapram and found clonidine was equally potent to meperidine and its 
role as an  anti shivering drug.  
 
Trekova NA et al, in 2004 conducted a double blind study to evaluate 
the effect of Tramadol in the treatment of post- operative shivering. The 
study was undertaken in 2 groups, 50 patients each in  tramadol and  
placebo  group, tramadol  at 1-2 mg/kg  completely stopped the  shivering  
post operatively and  reduced  intensity  in 49 patients (98%) They found 
mild sedation compared to placebo group and concluded  tramadol   is  
effective  in  post anaesthetic shivering. 
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 In  a  review  article  by Pradip K.Bhattacharya,  Lata Bhattacharaya, 
et al in 2003;on  mechanism of action of tramadol in the treatment  of  post 
spinal  anaesthesia shivering, concluded  that tramadol is  an  anti-shivering  
drug  with  similar  mechanism  of  nefopam  which is  an  analgesic 
NSAID. It inhibits the reuptake of NA, 5 HT and dopamine  and  facilitates  
5HT release. Cerebral 2 adrenoceptors play a role in the attenuation of 
shivering by tramadol. They concluded that tramadol can  be  used  to  treat  
post-anaesthesia  shivering.  
 
Sessler studied “thermoregulation under anaesthesia” and various 
modes of  temperature  monitoring  in  2000;  he observed core temperature 
is  the  best  single  indicator  of  thermal status in humans, and monitored 
at the tympanic membrane, pulmonary artery, distal oesophagus and 
nasopharnyx. Axillary temperature are reasonably accurate but work best. 
Core temperature should be measured during regional  anaesthesia  in 
patients  who  become  hypothermic.   
 
Most ascending thermal information  traverses via  spinothalamic 
tracts  in  the anterior spinal cord but no single spinal tract is critical in 
conveying information. Central thermoregulatory control is impaired in 
regional anaesthesia. Cold  signals  from  the  skin  travel via A delta fibres, 
whereas  warm   signals  are  transduced  by  unmyelinated c  fibres. During  
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regional anaesthesia,  core hypothermia is  associated by increase in skin 
temperature. The paradoxical result is perception of increased warmth 
accompanied by shivering from automonic thermoregulatory response.  
 
Jan De witte and Sessler DI in a review article written in 2002; stated  
that  tramadol  is similar  to nefopam  in  its mechanism  of action as  an   
anti-shivering drug. In  human volunteers, a high dose of naloxone only  
partially  reverses  the anti shivering  effect of tramadol, cerebral alpha 
receptors are thought to play a role in the attenuation of post operative 
shivering by tramadol. 
  
                      Bhatnagar  et al, in 2001; studied  the pharmacological control  
of shivering  using  tramadol and  pethidine. They  conducted  a 
randomized double blind trial with 30 ASA patients of grade 1 or 2 patients  
and evaluated the efficacy of  tramadol and pethidine  in  the treatment  of  
post  anaesthetic shivering. Patients  received  either tramadol  1mg/1kg  or  
pethidine 0.5mg/kg iv.  The grade of shivering pulse rate, blood pressure 
and respiratory rate were observed  every 10mts for 1 hour, shivering was 
significantly ceased in the tramadol group (P<0.05). No  patients  receiving  
tramadol  had  recurrence  of shivering, and they concluded  that  iv 
tramadol  1mg/kg is  more  effective than pethidine 0.5mg/kg  for  the  
treatment of post- anaesthetic shivering. 
 13
Buggy DT and crossly AW, British Journal of anaesthesia 2000 
reviewed  thermoregulation  and  post anaesthetic shivering. They observed 
120  obstetrics patients, among them  33%  of patients   had shivering  after  
epidural  anaesthesia  and  concluded that shivering was due to impairment 
of physiological set points and also concluded  that combined general and  
epidural anesthesia cause more fall in  core temperature  than   epidural  
anesthesia only.  
 
Delaunayh, SesslerDI et al,  1999 concluded  that clonidine decreases 
the thermoregulatory thresholds for vasoconstriction and shivering in 
humans. 
 
 Wang JJ, et,al, in 1999;  conducted a  prospective double blind 
randomized study and evaluated the potency of nalbuphine with meperidine 
and saline for  treating  post anaesthesia shivering. 90 patients of  ASA I & 
II  patients included in the study,  were divided  into  three groups, 30  each, 
who  received Inj. nalbuphine 0.08mg/kg, and Inj. meperidine 0.4mg/ kg 
and saline iv. The response rate after 5mts was noted. Both nalbuphine and 
meperidine provided a rapid and  potent  anti shivering  effect  with  high  
success rates of 80% and 83% and 0% (P<0.01). The differences between 
nalbuphine and meperidine were not significant. They concluded 
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nalbuphine may be an alternative to  meperidine  for  treating  post 
anaesthesia shivering.  
  
           Sebastiano mercadante, et  al  in 1994, studied  the effect of 
clonidine on  shivering  after  epidural analgesia. A randomized controlled 
double  blind  study  conducted on  sixty obstetric patients who developed 
shivering  after  receiving   epidural analgesia  were  randomly  allocated  to  
treat  with  clonidine  150µg,  and  meperidine 50mg iv (n=20)  or saline (n-
20). After injection of  drugs  patients  were, evaluated  at  5mts intervals, 
clonidine was effective as meperidine in controlling shivering and  caused  
reduction in  heart rate. Drowsiness  noted in both groups. Thus  they  
concluded  that  clonidine was effective in controlling shivering  at  an  
acceptable  level of drowsiness. 
 
 Bansal  P. Jain  G.1999  conducted  the  study on control of shivering 
with clonidine, tramadol and  butorphanol under spinal anaesthesia to 
compare the efficacy and side effects. This randomized control  prospective 
study was conducted on 90 patients undergoing various  abdominal and 
orthopedic surgeries. Those patients who developed   shivering  were  
randomly  allocated to receive tramadol 50mg, butorphanol  1mg  and  
150µg   clonidine in a double blind manner. Control of  shivering, time 
taken  for cessation,  recurrence,  hemodynamic  changes,   axillary  
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temperature  and side effects were noted; collected data were analysed  
using statistical tests. They found butorphanol and tramadol were more 
effective than clonidine. Butorphanol,  tramadol  and  clonidine  suppressed  
shivering  in  83%, 73%  and  53%  of  patients ,time  taken to  terminate 
shivering was higher with  clonidine  (3.3±0.9mts)  than butorphanol  and  
tramadol (2.1± mts) and  1.8 ± 0.5 mts  (P<0.001).   
 
Chan and co-workers in 1999 investigated the dosage of tramadol 
which was effective in  controlling  shivering  under  regional  anesthesia in   
obstetric  patients  in  randomized  double  blinded  study    on   36 patients,  
12 were allocated to 0.5mg/kg  tramadol group, 13 were allocated to 0.25 
mg/kg  tramadol  group and 11 were allocated  to 0.05 ml/kg normal  saline  
group. Shivering  was  controlled   in  80%  patients  in  0.5 mg/kg  group, 
92%  patients  in  0.25% mg/kg group, and 27%  in Normal saline group. 
They concluded that intravenous tramadol controlled shivering  in  obstetric  
patients and no demonstrable difference in response  rate or  incidence of  
side effects  between  the  two  doses  0.5mg /kg  and  0.25mg/kg.  
 
          S Sia in 1998, BJA, studied  the efficacy  of  clonidine   to  prevent  
post extradural  shivering  in  100 healthy patients  who received extradural  
block  for  knee  arthroscopy. It was a prospective randomized double  
blind study. Patients (n=50) were allocated into 2 groups just before  
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extradural anaesthesia, group I (n=50) received iv clonidine 1µg/kg and  
group II (N=50) received  iv  saline bolus.  The heart rate, arterial  blood  
pressure, spo2, cutaneous  temperature, level of sedation were  all  recorded  
at  baseline, after  10,20,30,40,50 60 mts, shivering was  graded  as  
moderate or severe, 3  patients in group I and 19 patients in  group II  had  
shivering  (P<0.0001) .There  is  no significant differences  in  parameters  
during  the study in arterial blood pressure,. Heart rate, spo2, cutaneous 
temperature and level of sedation. They concluded iv clonidine 1mg/kg  
provides significant reduction in the incidence of  shivering, without  any 
adverse side effect.   
 
Capogna and D cellano  in  1993;  BJA, studied the  efficacy of iv 
clonidine to suppress post extradural shivering in parturients. 40 parturients 
who received extradural  block  for  labour  (n=20) and casearean section 
(n=20) and who  requiring   treatment  for  shivering  after  delivery were 
allocated into 2 groups; group I  received iv clonidine 30 µgm and 
maximum of 90 µgm iv given; and Group II received iv saline 5ml. After 
15mts,  patients who received clonidine  with stopping of shivering within 
5 mts were 75%, in  contrast  to  no improvement  in saline group.  Arterial 
pressure, heart rate, core and peripheral temperature, spo2 did not differ 
significantly between groups. They concluded that a small dose of i.v  
clonidine is enough to  suppress  extradural  shivering  in  parturients. 
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PHYSIOLOGY OF SHIVERING 
  Normal  body  temperature is  36.5-37.50 C. Core body temperature 
is  maintained  near  a constant level  through thermo regulation. However 
when  exposed  to  cold environment ,  the  internal  mechanism is unable to 
replenish heat  that  is  lost to the surroundings.  Hypothermia  is  
defined as any body  temperature  below 350 C (950F). It is subdivided as  
       Mild (32-350 C)  
 Moderate  (28-320C) 
 Severe (20-280 C)  
 Profound ( less than 200C) ] 
 
Shivering20  is a  bodily defense function in response to early 
hypothermia  in  warm blooded  animals. When the core temperature drops, 
The  shivering reflex  is  triggered. Muscle groups  begin  to shake in  small 
movements in  an  attempt  to create  warmth by energy. Increased muscle 
activity results in heat generation. Shivering is also observed  in fever,  
though  their core temperature is elevated already.  
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Fig:1 Thermo Regulatory centre 
 
  The thermoregulatory system coordinates defenses against cold and 
heat to maintain internal body temperature to optimise the metabolic 
function. The organisation of the thermoregulatory system particularly 
in the post anaesthetic shivering is discussed below: 
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Neuronal networks controlling thermoregulation 
     Multiple inputs from various thermo sensitive sites are 
integrated at numerous levels within the spinal cord and brain to provide 
networks controlling thermoregulation. Three components of 
thermoregulation  includes  thermosensors and afferent neural pathways,  
integration  of thermal inputs , and effector pathways for autonomic  and  
behavioral effects.  
 
I. Thermosensors and afferent neural pathways – 
A. Spinal cord:    
 Cold  signals  from skin travel primarily through Aδ nerve 
fibres whereas warm signals travel  through  unmyelinated c fibres, 
both  detect cutaneous  temperature. Recently it appears that 
Transient receptor potential protein receptors  in skin and dorsal 
root ganglia are fundamental temperature  sensing  element  both 
in skin and dorsal root ganglia, which are highly temperature 
sensitive. TRPV1- 4 receptors  are  heat  activated  and TRP M8 
and A delta are activated  by cold. All afferent cold sensitive 
neurons are modulated at spinal cord level  which is carried by 
lateral spinothalamic  tract to hypothalamus. 
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B. Extra hypothalamic Brain stem  
Two groups of  neurons are involved in thermal response and control  
of  muscle tone and shivering. Nucleus raphe magnus and  subcoerules area 
.In medulla, nucleus raphe magnus has high percentage of serotonergic  
neurons  which  responsed to warmth. The locus subcoeruleus is an area in 
pons, ventromedially which contain noradrenergic neurons, which  
responsed  to  cold. These  areas behave as relay stations and responsible 
for modulation of thermal afferent information.  
 
II. Integration of Thermal inputs  
 The preoptic region of the anterior hypothalamus is the dominant 
autonomic   thermoregulatory  controller. Excitatory input from the  warm 
sensitive neurons comes from the hippocampus which links the limbic 
system to thermoregulatory responses. The warm sensitive neurons not only  
sense  core temperature but also compare the thermal and non thermal 
synaptic afferents. Thus anterior hypothalamic neurons act as sensors  as  
well  as  integrators. 
 
III. Effector Responses and  Effective   mechanisms  
Effector Responses 
1. Sweating,  
2. Peripheral cutaneous Vasoconstriction 
3. Brown fat metabolism  
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Effective   mechanisms 
1. Shivering (Postural and locomotive muscular activity)  
2. Vasomotion (Blood pressure and osmotic control)  
3. Behavioural Regulation (powerful effector)  
 
Shivering and Non shivering thermogenesis: 
It is an involuntary oscillatory muscular activity augmenting heat 
production. Vigorous  shivering9 increases heat production upto 600% 
above  baseline. The fundamental tremor  frequency on Eletromyogram is 
near  200Hz in  humans.  Normal shivering is modulated by  a  slow 4-8 
cycles/mt  waxing  and waning  pattern. Increased  muscular activity results 
in the generation of heat. In shivering the heat is the main product utilized 
for warmth.  
 
New born babies, infants and young children  experience greater heat 
loss than adults  because they cannot  shiver  to maintain heat. They rely  
on  non shivering  thermogenesis. Children have an increased amount  of  
brown adipose tissue. When cold stressed , they will release norepinephrine 
which reacts with lipases in brown fat. The energy is produced  in  the  
form  of  ATP  by Non Shivering Thermogenesis9. 
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Fig:2 PHYSIOLOGY OF POSTANAESTHETIC SHIVERING 
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Vasomotion: 
Most  metabolic heat lost from skin is prevented by vasoconstriction, 
an  autonomic  effector mechanisms9. Total digital blood flow  is  divided  
into  nutritional (mostly capillary) and thermo regulatory (mostly 
arteriovenous shunts)  components. Roughly 10% of cardiac output  
traverses these arteriovenous shunts and consequently increases mean 
arterial pressure  by 15mm Hg.  
 
 Heat loss is normally  regulated without major responses of 
sweating or shivering because cutaneous vasodilatation and 
vasoconstriction is enough  to control heat loss. Thermoregulatory 
vasoconstriction   decreases  cutaneous  heat loss  and constrains metabolic 
heat to the core thermal compartment. This prevents body temperature from 
decreasing by 10C which is required to activate intraoperative shivering. So  
shivering  is  a  last  resort defense.  
 
  Shivering9 is elicited from the preoptic region of the 
hypothalamus. Efferent  signals  descend  in the  medial forebrain bundle. 
Although pre optic region suppress  shivering by inhibition of posterior 
hypothalamus, evidence is lacking. The neuronal activity in the 
mesencephalic  reticular formation  and dorso lateral pontine and medullary 
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reticular formation  exhibit  descending  influences  on the spinal cord  
which increase muscle tone.  
 
   Spinal alpha motor neurons and their axons form the final 
common path, both co-ordinated movement and shivering, synchronization  
of  motor neurons may be mediated by recurrent inhibition  through  
Renshaw cells, inhibitory neurons identified. 
 
Heat Transfer  
Normal mechanism of  heat loss4 includes 
I. Conduction 
II. Convection 
III.  Radiation  
IV.  Evaporation 
 
Conduction4 heat  loss are negligible during surgery. It is heat transfer 
between two adjacent surfaces. Convection heat loss is the important  
mechanism by which heat is transferred from patients to the environment. 
It increases in operating rooms equipped with laminar flow. Sweating 
increases cutaneous evaporative loss   enormously but is rare during 
anesthesia. 
 25
 All surfaces with a temperature above absolute zero radiate heat. All 
surfaces absorb heat radiating from surrounding surfaces. Heat transfer 
via this mechanism is proportional  to the difference of the fourth power 
of the absolute temperature difference between the surfaces. Radiation is 
the major type of heat loss in most surgical patients. 
 
Temperature Monitoring 
 Core temperature monitoring9 is used to monitor intraoperative 
hypothermia, prevent over heating and facilitate detection of malignant 
hyperthermia .Core temperature  can be accurately monitored at  four  sites, 
the  tympanic membrane, pulmonary artery, distal oesophagus and 
nasopharynx. It can also be reliably  estimated from  mouth, axilla, and 
bladder.  
 
Fig:3  Thermometer  
 
 
 
Mercury in glass  thermometer are slow and cumbersome and spilt  
mercury is a biohazard. The most common electronic thermometer are 
thermistors  and thermocouples. Thermistors are temperature sensitive semi 
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conductors whereas thermocouples depend on the tiny current generated  
when  dissimilar  metals are joined. Both devices are sufficiently  accurate 
for  clinical use and inexpensive. 
 
TEMPERATURE REGULATION 
 The slope of response intensity4 versus core temperature define the 
gain of  the thermoregulatory response. When  the response intensity, no 
longer increasing, with further deviation in core temperature identifies  the 
maximum intensity.  This system of thresholds and gain is a model for a 
thermoregulatory system. 
 The mechanism by which the body determines absolute thresholds of 
temperatures   is  unknown.  But it appear  to   be  mediated  by 
neurotransmitters  like NA, dopamine, 5HT, Acetylcholine, Prostaglandin 
E1  and neuropeptides.  Control of autonomic  responses is 80% determined   
by thermal inputs   from  core structures. Temperature is regulated by  
hypothalamus  that  compare  integrated  thermal inputs from  skin surface, 
spinal cord and deeper tissues . In human inter  thresholds range is usually 
0.2 – 0.4-°  C,  which  is      bounded    between  sweating  and 
vasoconstriction  thresholds. 
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Fig. 4 Temperature Regulation 
 
Thermo regulation during general Anaesthesia  
 Major disturbances are observed during and after general 
anaesthesia in thermoregulation. The induction of general anaestheisia 
impairs the function of neurons in the preoptic nuclei and hypothalamus 
thereby cause slighty elevated warm response thresholds whereas cold 
response thresholds are markedly   reduced. Behavioural adaptations are 
not  relevant  under  general anaesthesia  when  paralysed  and unconscious. 
All general anaesthetics inhibit autonomic thermo regulatory control. It 
slightly elevates warm response and reduces cold response threshold. The 
interthreshold is increased from 0.30C to approximately 20-40C . The gain  
and maximum  intensity of sweating  are best  preserved  whereas the 
thresholds for vasoconstriction and shivering are  markedly  reduced by 
general anaesthesia.  
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Thermoregulation during regional anaesthesia  
   Spinal anaesthesia9 and epidural anaesthesia decrease the 
vasoconstriction  and shivering thresholds to a comparable degree by 0.60C, 
but  to lesser  amount  at the level above the upper level of the block. The  
gain  of shivering  is  reduced  and maximum intensity of shivering is 
reduced  in  regional anaesthesia. This occurs due to shivering above block 
compensates for the inability of muscles below the block to response in 
shivering. The core  temperature decreases by 0.6-1.50C during the epidural 
anaesthesia in the first hour is due to core to peripheral  redistribution  of 
heat and epidural vasodilatation. However with prolonged epidural 
anaesthesia,  the degree of core hypothermia is less than that of general 
anesthesia. This is explained that vasoconstriction above the block 
compensates for heat losses in epidural Anaesthesia.  
 
 
Fig:5 Thermoregulatory threshold in Normal humans 
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 Fig:6 Thermoregulatory threshold in Anaesthetised humans 
 
Shivering9 during regional anaesthesia like that of general anesthesia  
preceded  by core hypothermia. It has same electro myography 
characteristics as that of general anaesthesia.  
 
 Interestingly core hypothermia may not trigger a sensation of cold 
during regional anaesthesia this may reflect the fact that subjective cold 
perception depends on afferents  and cutaneous vasodilatation, leading to 
sensation of warmth although accompanied by thermoregulatory shivering. 
Awareness of core hypothermia is impaired by epidural anaesthesia.  
  
After the core to peripheral redistribution of body heat with induction 
of regional anesthesia, subsequent hypothermia depends on balance of 
cutaneous heat loss and  metabolic heat production.. The vasoconstriction 
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and shivering threshold are reduced by regional anaesthesia which is  
further  reduced  by adjuvant drugs and advanced age.  
 
 Shivering Patterns  in intraoperative  hypothermia 
Has four potential patterns:  
1. Normal thermoregulatory shivering in response to core Hypothermia.  
2. Normal shivering in Normothermic  patients.  
3. Stimulation of cold receptors by local anesthetic drug.  
4. Non thermoregulatory muscular activity resembles  shivering.  
  Electromyographic studies indicates tremor has 4-8 cycles/mt waxing  and     
waning  pattern  in normal shivering.  
  
Fig:7  Shivering patterns 
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Skin temperature contributes to 20% of thermoregulatory responses. 
Hence shivering is treated by warming the skin surface, which contributes 
to 20%  of  thermoregulatory control. 
  
                 To summarise, General anaesthetics and opioids have less 
influence on sweating but the gain and  maximum  intensity   of sweating 
slightly increased. Whereas the thresholds for vasoconstriction and 
shivering are markedly reduced. In regional anaesthesia, central 
thermoregulatory control is slightly impaired.The  vasoconstriction and 
shivering thresholds are comparably decreased. The gain and maximum 
response intensity of shivering are reduced. Finally behavioral 
thermoregulation is impaired.   
 
Origins of postanaesthesia shivering  
Several  hypothesis9  raised to explain the origins of post anaesthetic 
shivering which include perioperative hypothermia,  the direct effect of 
anesthetics, post operative pain, hypercapnia, respiratory alkalosis, hypoxia, 
existence of pyrogens, early recovery of spinal reflex activity  and 
sympathetic over activity. For more than 10 years,  different  studies  
provided  clearer insight into the origins of anaesthesia induced shivering. 
One hypothesis, explain the clonic movements corresponds to spinal reflex 
hyperactivity, resulting from inhibition of descending cortical control by 
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residual anaesthetics. These EMG signals9 are compatible with the clinical 
description of abnormal reflexes during the  early  recovery phase.  
  
 Another existence of a link is between post-operative pain and 
incidence of shivering; which was confirmed by a study comparing the 
frequency of shivering after intra-articular lidocaine who underwent knee 
arthroscopy. Those patients with severe pain who did not receive local 
anaesthesia was accompanied by higher incidence of  post anaesthetic 
shivering.  
 
    Most frequently tested and proposed hypothesis is anesthesia 
induced hypothermia and resulting thermo regulatory shivering. EMG 
analysis of shivering patterns are similar during anesthesia and hypothermia 
in normal population. Of all the different hypothesis, to explain the 
incidence of post anaesthetic shivering, only peri operative hypothermia 
and  pain   have  been clearly explained.  
 
 Consequences of Post aneasthetic shivering                                                                      
                            The first consequence of post anesthetic shivering is 
discomfort and stressful sensation. Another consequence is increased pain 
caused by muscular contractions on the operated site, and tension of suture 
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line. Following  ophthamological surgery, shivering increases intra ocular 
pressure and may worsen the morbitidity.  
          
                      Shivering is perceived as unpleasant experience by the 
parturient under regional Anaesthesia. Ostherimer and Datta noted that “Of 
all the side effects associated  with anesthesia and birth, shivering alone 
was the only symptom as a disconcerting and unacceptable”. The main 
effect of  post anaesthetic shivering  is  the increase in oxygen consumption 
Vo2 approximately 40-120% by affecting several muscle groups; shivering 
triggers increase in metabolic demand combined with increased  minute 
ventilation. Sometimes the metabolic demand can exceed the capacity to 
deliver oxygen and it is quite rare, to result in anaerobic metabolism.  
                       
Prospective randomised data suggested that the high risk patients 
with  reduction  in Core temperature  by 1.3C were three times more likely  
to  experience  adverse myocardial outcomes due to marked increase in 
plasma catecholamines. Mild hypothermia doubles the incidence of  morbid  
cardiac events  in patients with coronary disease and hence strategies to 
prevent perioperative shivering is mandatory for the comfort  and safety  of 
the patients.   
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Measures to combat shivering 
      (1) Passive insulators9  
         Cotton blankets, surgical drapes,  disposable plastic draps, plastic 
bags are passive insulators which  reduce  heat loss to  environment. Heat  
conservation is directly proportional to area covered. A single layer 
covering material decreases  approximately  30%  heat loss. Unfortunately 
adding layers do not increase the benefit. 
 
(2) Active warming system  
        In Convection warming system, when warmed air is forced 
through a quilt like porous blanket covering the body. It replaces air 
envelope of  normal  body with a warm air envelope. This is the most 
effective system for conservation of  body heat  (Bair Hugger unit).  
Radiant  heat system  like infrared light,  thermal ceiling lights are used for 
warming. Other measures  like warming inspired air, warming intravenous 
fluids, blood and blood components before infusion. Maintaining post 
operative environment at 240C are useful in preserving body temperature 
and reducing shivering 
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3) Pharmacotherapy20  
            Potent anti shivering properties have been attributed to many 
drugs. These include biogenic monoamines, cholinomimetis, cations,  
endogenous  peptides  and NMDA receptor antagonists.   All these drugs 
appear to modulate the central thermoregulatory control mechanisms. 
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NALBUPHINE – PHARMACOLOGY 
 
   Nalbuphine is a semi-synthetic opioid agoinst antagonist analgesic 
which belongs to phenanthrene series. It is chemically similar to opioid 
antagonist,  naloxone and naltrexone and oxymorphone.  
 
(–)-17-(cyclobutylmethyl)- 4,5α-epoxymorphinan- 3,6α,14-triol hydrochloride 
 
Fig:8 Chemical Structure of  Nalbuphine 
 
Preparations  
 It is available in two formulations. 10mg/ml and 20mg/ml of 
Nalbuphine  hydrochloride.  Both strengths comprise of 0.94% sodium 
citrate hydrous, 1.20% citric acid anhydrous, 0.1% sodium metabisulfite 
and 0.2% of 9:1 mixture of methyl paraben and propyl paraben as 
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preservatives  where as 10mg/ml  contain  0.1%     sodium  chloride.   It is 
soluble in water and ethanol, available as  an injectable solution.  
 
Pharmaco kineties  
Nalbuphine is a potent analgesic, its potency equivalent to that of 
morphine on a milligram basis. Its oral administration is three times more 
potent than codeine.  
 Onset of action occurs within 5-10mts after intravenous 
administration.  
 Its plasma half life is 5 hrs  
 Duration of analgesic activity has been in the range from  3-6 
hrs.  
 The opioid antagonist activity of nalbuphine is one fourth as potent 
as nalorphine and 10 times that of pentazocine.  
 
MECHANISM OF ACTION 
 The exact mechanism of action is unknown. But it interacts with µ 
opioid  receptors and delta opioid  receptors by competitive inhibition. It 
acts as agonist at kappa opioid receptor and its interaction with kappa 
opioid  receptors is responsible for its analgesic and anti shivering property. 
Activation of supraspinal and spinal k receptors results in less respiratory 
depression, sedation and  limited analgesia. 
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ADVANTAGE OF NALBUPHINE 
 An important difference between nalbuphine and pure opioid 
analgesia is the ceiling effect on respiration. The ceiling effect is that 
increase in  dose >30mg  do not produce  further  respiratory depression in 
absence of  other drugs affecting respiration.  Nalbuphine has limited 
ability to depress respiratory function4. When  administered with concurrent 
µ-agonist analgesics eg.morphine, fentanyl, it may partially reverse or 
block opioid induce respiratory depression.  Nalbuphine4  10 mg/ml caused 
no significant changes in systemic, pulmonary ,arterial and pulmonary 
capillary  wedge pressure. 
 
Clinical uses  
1) It is used for the relief of moderate to severe pain  
2) Used as a supplement to balanced anaesthesia for pre-op and 
postop analgesia  
3) For obstetrical analgesia during labor and delivery  
4) In addition to relief of pain,  
5) It is used as a treatment for morphine induced pruritis.  
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Overdose and side effects: 
                     In case of overdose, the specific antidote is Naloxone. 
Tolerance to side effects of  nausea, sedation and cognitive symptoms are 
seen. Nalbuphine  has less  ability to depress respiratory function than other  
pure µ-opiod analgesic drugs. 
 
    Other  side effect is  sedation and less frequent side effects  are  
nausea, vomiting , dizziness, vertigo, dry mouth and  headache. Other  rare  
side effects  (include <1%)  are CNS side effects like restlessness, euphoria 
hallucinations  and CVS side effects like hypotension, bradycardia, 
pulmonary edema and GI cramps, dyspepsia.  
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PHARMACOLOGY OF TRAMADOL 
 
Tramadol is a synthetic, centrally acting analgesic agent which is 
structurally related to codeine and morphine. It is a racemic mixture of 2 
enantiomers, which enhance analgesic actions. It was first synthesised by 
Grunenthal in 1962.  
 
 
 
Fig:9  Chemical Structure of  Tramadol 
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Mechanism of action   
Tramadol act synergistically on descending inhibitory pathway in the 
CNS, resulting in the modulation of second order neurons in the spinal 
cord. These inhibitory pathways mediated by the raphe nuclei, 
periaqueductal grey, locus coeruleus and  reticulospinal projections involve 
both opioid and monoamine neurotransmitters. In healthy volunteers, it 
decreased sweating, shivering thresholds, and vasoconstriction and these 
effects were partially reversed by naloxone.  
 
Tramadol  unique dual mechanism of action like weak opioid 
agoinst,it stimulates  µ receptor and weak NA and 5-HT reuptake inhibitor 
synergistic actions enhance its analgesic effects. It activates spinal  
inhibition  of pain  by decreasing the reuptake of NA and  serotonin 
Tramadol is one fifth to one tenth as potent as morphine. 
 
Pharmaco kinectis  
  It is available in various forms  
1) Solutions for IV, IM, SC administration  
2) Formulations for oral like capsules, tablets or drops. Sustained 
release formulations are also available.  
3) Suppositories for per rectal administration  
4) Preservative free forms are used in epidural blocks and 
neuromuscular blocks.  
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Absorption 
Tramadol is rapidly absorbed after intramuscular injection. C max of 
166µg/L is reached in 0.75 hrs after 50mg intramuscular injection. 
Intravenous and intramuscular infusion are bioequivalent in respect to 
systemic bio-availability. Cmax values of 355-369 µg/L reached in                
0.9 hrs and 1.1 hrs after intra muscular injection of 100mg of tramadol.  
 
Distribution  
        It is rapidly distributed with a half-life of 6 minutes in the initial 
phase followed by a slower distribution phase of 1.7 hrs. The total volume 
distribution of 306L  after oral & 203 L after parentral administration 
indicates high tissue affinity, its plasma binding is 20% brain peak 
concentration of tramadol occurs after 10mts of oral administration and 
those of its major active metabolite o–desmethyl tramadol(M1) 20-60 mts 
after oral administration. Tramadol crosses the placental barrier with 80% 
maternal concentration in umbilical venous various plasma. Very small 
0.1% excreted in breast milk.  
 
 
 
 
 
 43
Metabolism and Elimination   
 Tramadol undergoes extensive first pass metabolism in the liver via 
two main metabolic pathways CYP3A and CYP2 D6, only one metabolite 
is active. About 10-30% eliminated in urine as unmetabolised form. It is 
excreted via kidneys 90% and 10% via  feces. 
  
 
Fig 10: Tramadol metabolites 
Age  
 The pharmaco kinetis is not age dependent; according to available 
studies there is no pharmacokinetic difference between adults and children. 
However elimination is prolonged in elderly peoples. 
Renal & Hepatic Diseases  
                  Since tramadol  is eliminated renally, its elimination is 
relatively prolonged in hepatic and renal disorders. In patients with 
advanced cirrhosis its elimination half life is extended to a mean of 13 hrs 
to 22 hrs.  
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Drug Interaction 
Tramadol is metabolized by CYP3A and CYP2D6 enzymes, Drugs 
acting on these enzymes, should be used with utmost care. It includes, 
cimetidine, quinidine,  fluoxetine, carbamazepine, amitriptyline etc. MAOI 
inhibitiors and other drugs that  lower seizure  thresholds are used cautiously  
with  tramadol.   
Pharmaco dynamics  
 
Respiratory system  
   Opioids analgesics produce dose dependent respiratory 
depression, this is mediated by a decrease in the sensitivity of respiratory 
centre to CO2 which results in decreased   respiratory rate and tidal volume; 
clinically significant  respiratory depression is not noted at the 
recommended  dose of  tramadol  unlike other opioids  commonly  used. 
 
Cardiovascular system  
  It does not have effects on heart rate or blood pressure. No major 
side effects noticed in 57 cardiac risk patients posted for major surgery.  No 
effects on mean pulmonary artery pressure4, pulmonary capillary wedge 
pressure, strokevolume index and total peripheral resistance were observed. 
Tramadol 1mg/kg administered intravenously produced no significant 
change in heart rate and blood pressure in patients with unstable angina and 
myocardial infarction. 
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Gastrointestinal system  
 
 It causes minimal effect on gastro intestinal function when compared 
to other opiods. It causes minimal increase in gastric emptying and colonic 
transit time. Side effects noted are nausea, vomiting and altered appetite. 
Incidence of constipation is very less compared to other opioids.  
 
Central nervous system  
 
   Tramadol produces sedation headache dizziness, euphoria dysphoria 
and seizures. Incidence of seizures is less than 1% . Hence cautiously used 
in epileptic, alcohol and drug withdrawal patients and those on anti 
depressant therapy. It is known to have anti-convulsant property mediated 
by kappa receptors. Antidepressant effect is observed based on its 
monoaminergic uptake inhibition.  
 
Analgesic effects  
 
   The analgesic effect is due to synergistic activity of its racemate 
with metabolite O-desmethyl Tramadol, , The peak effect occurs 1 to 4 hrs 
after oral administration. Duration persists for 3 to 6 hrs after onset. 
Intravenous tramadol 2mg/kg provides similar effects on pain and tolerance 
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thresholds compared to pethidine 1mg/kg. Recent evidence suggests that 
hepatic demethylation by liver enzyme sparteine oxygenase  and 
CYP450/CYP 2D6 play a major role in mediating analgesic effect. 
 
Overdose 
 
   It can produce significant neurotoxicity like seizures, coma, 
respiratory failure, tachycardia and hypertension on over dosage.  The most 
common overdose symptoms are lethargy(30%), Nausea(14%) agitation 
(10%) ,seizures(8%), coma (5%), Hypertension (5%), Respiratory 
depression 2%. No serious cardiotoxicity noted on overdose. The risk of 
abuse with Tramadol is low.  
 
Uses 
 
1.  Tramadol  is used in the treatment of acute pain;   
2. Tramadol is used in patients with low pulmonary reserve like elderly, 
obese and preexisting cardiopulmonary diseases. 
3. Pain relief for surgical procedures of thorax and upper abdomen 
4. In patient control analgesia in surgical procedures including 
abdominal, orthopedic and cardiac surgery.  
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5. In day care patients 
6. Used in acute orthopaedic trauma and sports injuries. 
7. Used in patients with colicky abdominal pain and acute appendicitis 
8.  It is found to be effective in obstetric analgesia. 
9. Tramadol improve gastro intestinal recovery from abdominal 
surgery. 
10. It is beneficial in whom NSAIDS are contra-indicated like patients 
with peptic ulcers. 
11. It is cautiously used in patients with impaired renal, hepatic or 
cardiac function. 
12. Recently it has shown positive effects on immune system function. 
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PHARMACOLOGY OF CLONIDINE 
   Clonidine is centrally acting sympatholytic 2 adrenergic agoinst and 
imidazole receptor agoinst. It activates 2  adrenoreceptors and release 
acetycholine , noradrenaline,  dynorphine. The depressor effects of these 
transmitters modulate thermal inputs.Clonidine also reduces the thresholds 
for vasoconstriction and shivering.   
 
 
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine 
Fig:11 Chemical  Structure of Clonidine 
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Pharmaco kinetics:  
 
The oral  bio availability of clonidine  is 75 -95%. Its protein binding is 
about 20- 40% .Clonidine is  metabolized in liver to inactive metabolites 
and 72% is excreted in urine. Its plasma half  life  is  8hrs ,   average     of 
5-13hrs for single dose and 41hrs for repeated dosing. It can be  
dministered through oral, epidural, intra venous routes and transdermal   
and topical applicators are available. 
 
Mechanism of action.  
  Clonidine has high specificity towards the presynaptic α2  receptors in the 
vasomotor center located in brain stem.By acting on α2  receptor clonidine 
decreases presynaptic calcium level and subsequent nor epinephrine release 
with resulting fall in sympathetic tone and blood pressure. It has also been 
proposed that the anti hypertensive effect of clonidine is due to agonism on  
I1  receptor ( Imidazoline receptor ) which mediates sympathominhibitory 
action of  Imidazoline receptor to lower blood pressure. Its mechanism in 
the treatment of attention deficit hyperactivity disorder is to increase the 
nor-adrenergic tone in pre frontal cortex and also from the locus coeruleus.  
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Synthesis : 
    It is a 2-imidazoline derivative (2,6 dichloro phenylamino 
imidazoline) synthesized from 2,6 dichloroaniline the reaction of which 
with ammoniumthiocyanate gives N-(2,6-dichlorophenyl) thiourea. 
Methylation of thiourea  and subsequent reaction with ethylene diamine 
gives  clonidine.  
 
Withdrawal 
   Sudden discontinuation cause rebound hypertension due to rebound 
sympathetic outflow. It should be tapered slowly to avoid rebound effects. 
Reintroduction of clonidine in mild cases and both alpha and Beta blockers 
for more urgent conditions. Beta blockers should never be used alone to 
treat clonidine withdrawal as alpha vasoconstriction continues. 
 
Clinical uses  
1. Clonidine is commonly used as anti-hypertensive agent.  
2. Used for Attention deficit hyperactivity disorder. 
3. And used in the treatment of  tourette syndrome 
4. It is used for the withdrawal symptoms produced by long term 
Narcortics, alcohol and nicotine. 
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5. Used to treat psychiatric disorders including stress, sleep 
disorders, borderline personality disorder and anxiety 
disorders. 
6. It produces mild sedation can be used as premedication. 
7. It is used in Epidural analgesia extensively. 
 
Other Uses  
 It is used in restless leg syndrome, to treat facial flushing, redness 
with rosacea. It is topically used in diabetic neuropathy, Clonidine used for 
migraine headaches and hot flushes of menopause.  
 
Adverse effects  
   Principal adverse effects are dizziness, dry mouth, drowsiness and 
hypotension; dose dependent sedation, headache, fatigue and drowsiness 
noticed.  
 
Other side effects are anxiety, constipation, rashes, weight gain, 
erectile dysfunction. Uncommon,side effects are paresthesia, delusional 
perception, night mare,sinus bradycardia, raynaud’s phenomenon, itchiness 
& hives. Rare complications are atrio-ventricular block, alopecia, high 
blood sugar, nasal dryness and gynaecomastia.      
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MATERIALS AND METHODS 
 
STUDY TYPE :  
Observational  
STUDY DESIGN :  
  Prospective 
  Randomised 
  Clinical trial, double blinded 
 
STUDY POPULATION  
 The study is under taken at Raja Mirasudhar Hospital,Thanjavur 
during the period of September 2013 to September 2014. Institutional 
ethical committee approval was obtained. Informed written consent  was 
also obtained from participating patients.  
 
CASE DEFINITION 
Total of 75 patients from obstetrics aged between 20-30 years of 
ASA grade I or II undergoing elective and emergency caesarean section 
under spinal anaesthesia who subsequently developed shivering were 
included in this study. 
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Groups 
The Patients were randomly divided into 3 groups.  
1. Group T – 25 Patients who received 0.5 mg /kg tramadol 
intravenously.  
2. Group C – 25 Patients who received 0.5 µgm/kg of clonidine 
intravenously.  
3. Group N – 25 patients who received 0.1 mg/ kg of nalbuphine 
intravenously.  
 
Outcome Measure 
Primary Measure  
(i) To evaluate the efficacy of tramadol, clonidine and nalbuphine in 
controlling Post anaesthesia shivering after caesarean secction.   
 
Secondary measure 
I. Time of onset of shivering after spinal Anaesthesia 
II. Time interval of disappearance of shivering after the drug given iv. 
III. Side effects. 
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Inclusion Criteria 
 
1. Patients from obstetrics group aged between 20 – 32 years of 
ASA grade I and II undergoing elective or emergency casearean 
section who developed shivering after spinal anaesthesia  
2. Patients who gave a valid informed written consent.  
 
Exclusion Criteria 
1. Patients with significant systemic diseases like cardiovascular, 
renal, hepatic, respiratory or neurological diseases.  
2. Patients with thyroid disease, eclampsia, GHT, GDM and obesity 
3. Patients with known hypersensitivity to Tramadol clonidine and 
nalbuphine. 
4. Patients on long term Phenothiazines and  MAO Inhibitors 
5. Patients who did not give valid informed consent.  
 
Procedure 
 After getting informed written consent from all participating patients, 
this randomized double blind clinical study was conducted in our 
institution. Ambient temperature was noted, baseline vital parameters were 
recorded. iv fluid started with iv access of 18 G cannula. The volume of the 
local anaesthetic, use of vasopressors, volume of fluid is determined by the 
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attending anaesthesiologist and was not affected by inclusion in the study. 
Baseline preoperative axillary temperature was noted in all the patients. A 
standard double layered blanket was used to cover the chest and upper limb 
of the patient. All the preloading fluid and drugs were given at room 
temperature. Oxygen at rate of 5L / mt was administered through facemask 
to all parturients. Monitoring of NIBP, pulse oximetry, ECG was done 
throughout the procedure. Central neuraxial blockade was given with 
Inj. bupivacaine( 0.5%) 2ml for all casearean section as per protocol. 
Patients who developed Shivering after neuaxial blockade were included in 
the study. A total of 75 cases filling the above criteria were selected for 
study were randomly divided into one of the three groups.  
 
Group T - 25 Patients receiving 0.5 mg /kg Tramadol IV 
Group C - 25 Patients receiving 0.5 µgm /kg clonidine IV 
Group N - 25 Patients receiving 0.1 mg /kg nalbuphine IV 
 
Shivering was graded as follows as per Wrench which is as follows 
Grade 0   -  No shivering 
Grade 1   -  One or more of the following, piloerection,             
    peripheral vasoconstriction, peripheral cyanosis 
             or without visible muscle activity. 
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Grade 2    -  Visible muscle activity confined to one muscle 
    group. 
Grade 3 -  Visible muscle activity in more than one muscle 
    group. 
Grade 4    - Gross muscle activity involving the whole body.  
  
 All the patients who developed shivering of grade 3 or 4 of shivering 
were included in the study randomly divided in one of the three groups.  
Group T received  tramadol  0.5 mg/kg, Group ‘C’ received clonidine 0.5 
µg/kg and group ‘N’ received nalbuphine 0.1 mg/kg. 
 
Data Collection 
  The drug was administered by another personnel who is 
blinded to whether the drug contains clonidine, tramadol or nalbuphine. 
The same person assessed the effect of the drug administration based on the 
format provided. All the patients were assessed for grade of shivering, its 
disappearance, hemodynamic status and side effects if any. 
 
  Patients were observed at intervals of 1mt till 5 mts and 
thereafter 10,20,30,45,60 mts. Baseline pulse rate, BP, SPO2, Respiratory 
rate and temperature were noted, during shivering and after the drug 
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administration at regular intervals. Recurrence of shivering  and 
requirement of  additional dose were also noted. 
 
Sedation characteristics were noted and graded according to “Filos 
Sedation Score” as follows:  
 
 1. Awake and alert  
2. Drowsy, responsive to verbal stimuli.  
3. Drowsy, arousable to physical stimuli. 
4. Unarousable  
 
Statistical methods 
 
  Descriptive statistical analysis, was carried out in the present study. 
Results on continuous measurements are presented on mean ± 5D(min-
Max) and results on categorical measurements are presented at 5% level of 
significance. One way ANOVA test has been used to find the significance 
of study parameter between the three groups of patients. Chi square test has 
been used to find the significance of study parameters on categories scale 
between two or more groups. 
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Significant figures 
  Suggestive significance ( p value 0.05< p<0.10) 
  Moderately significance ( p value 0.01< p0.05) 
 Strongly significance ( p value p0.01) 
 
OBSERVATION AND  RESULTS 
 
 75 Patients of  Antenatal mothers  aged between 20-32 years of ASA 
grade I or  II under going caesarean section under spinal anaesthesia who 
developed shivering were included in the study.  
 
The patients were randomly allocated into three groups. 
 
Group – T 25 patients received 0.5mg /kg of tramadol intravenously. 
Group – C 25 patients received 0.5 µgm/kg of clonidine intravenously. 
Group – N 25- patients received 0.1mg/kg of Nalbuphine intravenously. 
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Table-1 
 Demographic Data : 
 
Age Distribution among groups 
 
Study 
Group Mean SD P Value Significant 
Group T 
Group C 
Group N 
25.80 
26.24  
26.84  
2.739 
2.773  
2.322  
0.375  
.> 0.05  
Not 
Significant  
 
  
The minimum age of the patient was 20 years and the maximum age 
was 31 years. The mean age of the patients in group T is 25.80+2.739 in 
group C is 26.24+2.739 , and group N=26.84 years. The statistical analysis 
is not significant for age (p=0.375) between groups. 
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Graph .1  Age Distribution Group 
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Table 2 
ASA GRADING 
 
 GROUP 
T 
GROUP 
C GROUP N TOTAL 
STATISTICAL 
INFERENCE 
I 20  (80%) 
17  
(68%) 
19  
(78%) 
56 
(74.7%) X2  = 098 
P= 0.611>0.05 
Not Significant II 5  (20%) 
8  
(32%) 
6  
(24%) 
19 
(15.2%) 
 
 
In the study , Group T has 80% ASA I patients and 20 % ASA II patients, 
Group C  has 68% ASA I patientsand 32 % ASA –II patients  and in group 
N, it is 78% and 24% for ASA I & II. The statistical analysis is not 
significant for ASA grading (p=0.611)  between groups. 
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Graph.2 ASA Grading 
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Table 3 
 
TIME FOR ONSET OF SHIVERING  
 
 
Study group Onset time Mean difference P value Significant 
Group T  
Group C 
Group N 
20.5 mts 
21.5 mts 
22.6 mts   
21.53%       
0.068>0.05      
Not   
significant 
 
The mean time for onset of shivering in group T was 20.5mts, and in 
the Group C was 21.5 mts and in group N was 22.6 mts . The statistical 
analysis showed the time of onset of shivering is not significant(p=0.68) 
between groups.  
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Graph .3 Onset of Shivering 
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Table 4  
 
TIME INTERVAL  FOR DISAPPEARANCE OF SHIVERING 
 
Group Mean (mts) SD P Value Significant 
Group T 
Group C 
Group N  
3.864  
2.184  
3.780  
0.25 
0.188 
0.410  
0.00< 
0.05  
Highly 
significant  
 
In this study the time interval for disappearance of shivering was 
noted, among groups. In Group T the mean time interval for disappearance 
was 3.864 +0.25mts, in Group C it is 2.184 + 0.188mts and in Group ‘N’ 
the mean time intervals is 3.78+0.410 mts. The ‘P’ value here is <0.00 
<0.05 which is highly signficant suggesting that clonidine group achieved 
lesser time for complete cessation of shivering when compared to tramadol 
and  naulbuphine group. 
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Graph.4   Time Interval  for Disappearance of Shivering 
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Table 5 
 
COMPARISON OF HEART RATE 
 
 
Time 
mts 
Group T Group C Group N Statistical Inference  
Mean
/Mt SD Mean SD Mean SD P Significant 
0 93.04 9.667 89.62 9.031 91.72 9.46 0.214>0.05 Not significant 
5 96.40 9.587 87.28 8.905 92.40 10.67 0.206>0.05 Not significant 
10 97.36 8.920 86.24 8.950 90.48 8.70 0.202 >0.05 Not significant 
20 97.12 9.558 84.24 8.293 88.72 9.217 0.218 >0.05 Not significant 
25 95.76 11.823 82.56 7.924 87.04 9.185 0.200 >0.05 Not significant 
30 94.88 10.741 81.60 7.483 85.92 8.878 0.210>0.05 Not Significant 
40 87.88 8.565 76.48 7.355 81.92 8.23 0.206>0.05 Not Significant 
50 84.32 8.219 73.36 6.897 80.80 9.32 0.208> 0.05 Not significant 
60 83.68 7.952 70.88 7.855 81.20 9.539 0.218> 0.05 Not significant 
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In the present study the heart rate variation was within 15% of basal value, 
among groups and there is no statistical significance between groups.    
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Graph.5 Trend of Heart rate 
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Table – 6     
 
COMPARISON OF SYSTOLIC BLOOD PRESSURE 
 
Time 
mts Group T Group C Group N 
Statistical 
Inference  
 Mean/ Mt SD Mean SD Mean SD P Significant 
0 mts 117.28 7.185 118.08 5.901 117.12 7.178 0.457> 0.05 
Not 
significant 
5 114.40 6.218 116.56 5.701 113.12 6.030 0.129> 0.05 
Not 
significant 
10 112.16 5.998 114.40 6.658 111.76 5.754 0.269> 0.05 
Not 
significant 
15 111.4 5.987 112.32 6.625 112.32 5.935 0.845> 0.05 
Not 
significant 
20 125.92 4.183 125.28 4.542 117.44 6.259 0.457> 0.05 
Not 
significant 
25 117.28 7.185 118.08 5.901 117.12 7.178 0.129> 0.05 
Not 
significant 
30 114.40 6.218 116.56 5.701 113.12 6.030 0.269> 0.05 
Not 
significant 
40 112.16 5.998 114.40 6.658 111.76 5.754 0.845> 0.05 
Not 
significant 
50 111.4 5.987 112.32 6.625 112.32 5.935 0.457> 0.05 
Not 
significant 
60 125.92 4.183 125.28 4.542 117.44 6.259 0.129> 0.05 
Not 
significant 
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In the present study, the systolic blood pressure between groups were 
recorded at 5 minutes interval and was within 15% basal values. There is no 
statistical significance between the groups.  
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Graph .6 Trend of mean systolic blood pressure 
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Table -  7 
 
COMPARISON OF  DIASTOLIC  BLOOD PRESSURE 
 
Time 
mts 
Group T Group C Group N Statistical Inference Significant 
Mean/
Mt SD Mean SD Mean SD P Significant 
0 mts 73.12 4.798 75.84 4.317 72.56 6.014 0.058 > 0.05 
Not 
significant 
5 71.0 3.786 74.64 3.451 72.40 5.859 0.052 > 0.05 
Not 
Significant 
15 69.92 4.142 73.20 3.559 71.36 6.264 0.060> 0.05 
Not 
significant 
20 73.12 4.798 75.84 4.317 72.56 6.014 0.058 > 0.05 
Not 
significant 
25 71.0 3.786 74.64 3.451 72.40 5.859 0.052 > 0.05 
Not 
Significant 
30 69.92 4.142 73.20 3.559 71.36 6.264 0.060> 0.05 
Not 
significant 
40 73.12 4.798 75.84 4.317 72.56 6.014 0.058 > 0.05 
Not 
significant 
50 71.0 3.786 74.64 3.451 72.40 5.859 0.052 > 0.05 
Not 
Significant 
60 69.92 4.142 73.20 3.559 71.36 6.264 0.060> 0.05 
Not 
significant 
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In the present study, the comparison of diastolic blood pressure between 
groups was within  10-15% of basal value , The statistical analysis reveals  
no significance between groups.  
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Graph .7 Trend of mean Diastolic blood pressure 
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Table 8 
 
COMPARISON   OF MEAN SPO2 
 
Time 
mts 
Group T Group C Group N Statistical Inference  
Mean% SD Mean SD Mean SD P Significant 
0 mts 98.5 0.507 98.5 0.504 98.5 0.507 0.799 > 0.05 
Not 
significant 
5 98.4 0.502 98.5 0.501 98.2 0.450 0.769 >0.05 
not 
significant 
10 98.4 0.500 98.3 0.502 98.3 0.479 0.748 >0.05 
Not 
significant 
15 98.3 0.479 98.2 0.479 98.5 0.506 0.434> 0.05 
NOT 
significant 
20 98.2 0.450 98.4 0.502 98.2 0.450 0.581 > 0.05 
Not 
significant 
25 98 0.365 98 0.450 98.4 0.502 0.302 > 0.05 
Not 
significant 
30 98 0.183 98 0.365 98.4 0.500 0.650 > 0.05 
Not 
significant 
40 98 0.101 97.5 0.183 98 0.265 0.321 > 0.05 
Not 
significant 
50 98 0.263 98.2 0.479 98.5 0.506 0.570 > 0.05 
Not 
significant 
60 98.5 0.507 97.8 0.346 98.2 0.456 0.477> 0.05 
Not 
significant 
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The Comparison of Mean SPO2 between groups showed a mean value of 
98- 98.5%.  The statistical analysis is not significant between groups. 
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 Graph .8 Trend of mean Spo2 
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Table: 9  
 
COMPARISON OF MEAN RESPIRATORY RATE  
 
Groups Mean Respiratory rate SD 
Statistical 
inference 
Group T (n=25) 23.84 0.473  
P value =0.06 
>0.05  
Not significant 
Group C (n=25) 20.96 0.200 
Group N (n=25) 21.92 0.277 
 
 
In this study, mean respiratory rate was compared, and there is no statistical 
significance between groups  
19.5
20
20.5
21
21.5
22
22.5
23
23.5
24
M
ea
n
Group T Group C Group N
 
Graph .9  Comparison of mean Respiratory rate 
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Table –10 
 
COMPARISON OF MEAN BODY TEMPERATURE 
 
Group Mean SD F P Significant
Group T 
(n=25) 
35.6240 0.14514 1.012 
0.368 > 
0.05 
N.S 
Group C  
( n=25) 
35.5840 0.14629    
Group N 
(n=25) 
35.6400 0.13844    
 
The comparison of mean body temperature between groups showed a mean 
value of 35.58 and the p value is not significant between groups.  
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 Graph.10 Comparison of mean body Temperature 
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Table -11 
 
COMPARISON OF SEDATION SCORE 
 
Group Mean SD F P Significant
Group T 
(n=25) 1.60 0.500 0.382 0.684>0.05 
Not 
Significant
Group C 
(n=25) 1.56 0.507    
Group N 
(n=25) 1.68 0.476    
 
 
 The comparison of sedations score between groups in our study 
showed a sedation’s score of 1.6 ± 0.5 which was statistically not 
significant.  
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Graph .11 Comparison of Sedation Score 
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Table -12 
 
COMPARISON OF SHIVERING SCORE 
 
Group Mean P Significant 
Group –T 3 NA NS 
Group –C 3 NA NS 
Group –N 3 NA NS 
  
Grades of Shivering  
 
 In our present study, the shivering grade of three was noticed in all 
the 3 groups. There is no statistical significance between the groups.  
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Graph .12 Comparison of Shivering Score 
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Table :13 
 
RECURRENCE OF SHIVERING 
 
Shivering Recurrence Groups 
 T (n=25) 
C  
(n=25) 
N  
(n=25) 
Total 
 n= 75 
Statistical 
Inference Significance
Nil 23 (92%) 25(100%)
23 
(92%) 71(94.7%) X
2 = 2.113 
Not 
significant 
Yes 2(8%) 0 2(8%) 4 (5.3% P = 0.348         >0.05 
 
 In our study there is no recurrence of shivering in group C, in Group 
T there were two patient with recurrence of shivering and in Group N  there 
were 4 patients with recurrence of shivering. The statistical analysis 
revealed there is no significance between groups.  
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Graph .13 Recurrence of Shivering 
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Table :14 
 
COMPARISON OF SIDE EFFECTS 
 
Comparison Group 
 T= n=25 C (n=25) 
N 
(n=25) 
Total 
(n=75 ) 
Statistical 
inference Significant
N 2 (8%) 0 0 2 (2.7%) X
2 = 15.441 
Df =6  
S 18(72%) 25 (100%) 
25 
(100%) 68(90.7%)   
S,N 2 (8%) 0 0 2(2.7%)   
Nil 3 (12%) 0 0 3(4%) P= 0.17 < 0.05 N.S 
 
 Comparison of side effects between study group showed two patients 
with nausea and sedations, two patients with nausea alone in Group T. In 
Group C and N all patients were sedated, statistical analysis showed no 
significance between groups.  
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Graph.14  Comparison of side effects 
 77
DISCUSSION 
 
  In Homeothermic species, a thermoregulatory system 
coordinates defenses against environmental temperature to maintain 
internal body temperature within a narrow range, thus optimizing normal 
body  function.  
 
  Hypothalamus is the seat of thermo regulation. The importance 
of thermal input form the skin surface was recognized in late 1950’s. In 
Early 1960’s physiologists found active thermoregulatory sites other than 
skin and hypothalamus, including extra hypothalamic portions of brain, 
deep abdominal tissues and spinal cord. Santario discovered the clinical 
importance of temperature in 1646, but it took two centuries before body 
temperature was recognised by wunderlich as a key parameter.  
 
  The importance of temperature monitoring was unknown till 
mid 1960’s when the first case of malignant hyperthermia was noticed. The 
combined effect of anaesthesia induced thermal impairment and exposure 
to a cool environment makes patients hypothermic in Operation Theatre; As 
pickering wrote in 195611 “The most effective way for cooling a man is to 
subject him to Anaesthesia”.  
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Spinal Anaesthesia is emerging as safe and popular technique both in 
elective and emergency surgeries. Incidence of post anaesthesia shivering is 
high. It occurs both during regional and general anaesthesia. Shivering is an 
unpleasant experience for the patients receiving spinal anaesthesia. At 
times, it is a sensation worse than surgical pain. It is physiologically 
stressful as it increases oxygen consumption, which go up by 100-600%. It 
interferes with monitoring like ECG, pulse oximeter and  NIBP. Shivering  
causes tension on sutures lines. It is detrimental to patients with low cardio  
respiratory reserve.  
 
 The exact mechanism of development of post anaesthesia shivering 
is not known; many hypothesis like perioperative heat loss, direct effect of 
certain anaesthetics, hypoxia, hypercapnia, uninhibited spinal reflex activity 
may contribute to shivering. 
 
 Many non–pharmacological methods like active and passive 
warming systems, warming of iv fluids, inspired air, blood and its products 
are tried in many studies. But these methods require use of specialized 
equipment which is not economically feasible and practical in clinical 
settings.  
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 Pharmacological methods are cost effective, when compared to non 
pharmacological methods. There is no gold standard drug for treatment of 
shivering. Many drugs like pethidine doxapram, ketabserin, propofol, 
physostigmine nefopam, clonidine, alfentanil, ondansetran, sufentanil are 
tried, with success rates ranging from 30-95%. Pethidine and clonidine are 
most commonly studied drugs. Pethidine is associated with nausea, 
vomitting and respiratory depression, whereas clonidine has lesser side 
effects and better hemodynamics.  
 
  Tramadol is a novel analgesic drug, It is a synthetic drug with 
opioid effect mediated via the mu-receptor, with minimal effect on kappa 
and delta receptors anti shivering effects of tramadol is mediated through 
inhibition of 5- HT3 and  NA reuptake. Tramadol inhibits 5-HT3 reuptake 
and promotes its release. It also inhibits synaptosomal noradrenaline 
reuptake,which contributes to its antishivering effect. 
 
  Electrophysiologic, neurophysiological and neuropharmacolo 
gical experiments in animals established role of noradrenaline and 
serotonin in the control of body temperature. Activation of nucleus raphe 
magnus, where serotonin acts as a neurotransmitter has inhibitory effect on 
shivering. The anti Shivering effect of tramadol is mediated by its effect on 
these receptors. 
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 Tramadol is likely to have better clinical utility as a anti-shivering 
drug. With its pharmacodynamic advantage in causing less sedation and 
less respiratory depression, it has potential use in the control of shivering 
and convenient and safer than meperidine.Tramadol in a dose of 0.5mg/kg 
is selected similar to the study conducted by Usha Shukla et al3.     
 
 Nalbuphine is a semi synthetic opioid agonist  antagonist  opioid 
analgesic with µ antagonist and kappa agonist activity. Its analgesic 
potency is equivalent to that of morphine. It has less ability to depress 
respiratory function, when compared to other opioids4.Nalbuphine in the 
dose of 0.1mg/kg is selected for the study similar to the study of O kyokong 
et al11.  
 
  Clonidine is a centrally acting selective 2 – agonist. It exerts anti 
shivering effects at three levels, hypothalamus, spinal cord and locus 
coeruleus. At the hypothalamic level, it decreases thermoregulatory 
threshold for shivering and vasoconstriction, since there are high density of  
2 receptors in hypothalamus. At  locus coeruleus,  a pro shivering centre 
in pons, clonidine reduces the spontaneous firing in locus coeruleus. At the 
spinal cord level, it activates 2 adreno receptors and release acetylcholine 
nor-epinephirine and dynorphine.  The depressor effects of these 
transmitters at dorsal horn modulate thermal inputs. Clonidine is highly 
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lipid soluble and crosses the blood  brain barrier and has quick onset. Due 
to these advantages, interaction of 2 adreno receptors at spinal and 
supraspinal occurs within the central nervous system . The dose of 
clonidine is selected as 0.5µg/kg which was similar to the study conducted 
by Kulshrestha et al1.  
 
In our study ,75 antenatal mothers who undergone caesarean section 
under spinal anaesthesia and developed shivering were included for 
treatment with study drugs namely nalbuphine, tramadol and clonidine. 
Group n (n=25) who received inj. nalbuphine, 0.1mg/kg, group c (n=25) 
who received inj clonidine 0.5µgm/kg and group t(n=25) who received inj 
tramadol 0.5mg/kg and data were collected as per protocol. 
 
 Statistical  analysis  of collected data showed no statistical 
significance among demographic datas, age distribution and ASA grading 
between three groups. The onset of shivering between groups were with a 
mean difference of 21.53 ± 2 minutes. It showed no statistical significance 
between groups.  
 
 The time interval for disappearance of shivering were noticed and 
found that Group  C with a mean of 2.184  ± 2 mts and p value of 0.000 
analysed by one way ANOVA test,  Group T with a mean time of 3.864 ± 
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0.2 mts and Group N with a mean time of 3.780  ± 0.25 mts. These results 
were similar by the study of Usha shukla et al in 2011, where they 
concluded clonidine was superior in controlling shivering than tramadol 
with significant side effects of nausea, vomiting and dizziness. 
 
  The recurrence of shivering after 15 mts of response time was 
noticed. In our present study, Group C showed no recurrence of shivering 
Whereas group – T showed recurrence in 2 patients (8%) and group –N 
showed recurrence in 2 patients (8%) with p value of 0.348>0.05; which 
was similar to the study conducted by oranuch  Kyokong et al  in 2007. 
They conducted a double blind randomnised controlled study of 280 
parturient with treatment for shivering after spinal anaesthesia. The 
recurrence rate of shivering and p value significance were similar to their 
study. They concluded that tramadol, nalbuphine were superior to 
ondansetron with low recurrence rates of shivering. 
 
The comparison of heart rate, systolic, diastolic, blood pressure 
respiratory rate, and mean Spo2 between groups showed no statistical 
significance which was similar to studies of Kranke P et al in 2004; who 
evaluated the efficacy of many pharmachological drugs in the treatment of 
shivering,  and concluded there is no significant difference in parameters of 
heart rate, arterial blood pressure, respiratory rate, spo2, cutaneous 
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temperature and  level of sedation. Which was  similar to study by S.sia et 
al; British Journal of Anaesthesia 1998 conducted a study with clonidine to 
suppress post extradural shivering in 90 parturients and concluded there is 
no significant difference in parameters of heart rate, arterial blood pressure, 
respiratory rate, spo2.  
 
The core body temperature was measured from axilla, before giving 
anaethesia and then when patients developed shivering .The mean body 
temperature was calculated and statistical analysis between three groups 
was 35.60, with a  p value of  0.368 ( P < 0.05 )  not significant. Sessler  DI 
et al studied the temperature monitoring and thermoregulation under  
anaesthesia” in 2002. They concluded that core temperature is the best 
indicator of thermal status of humans. Various sites of monitoring done  in 
tympanic membrane pulmonary artery nasopharynx distal oesophages. and 
also found that axillary temperature are reasonably accurate and best.  
 
    In our study, the sedation score as stated by “Filos” were used   for 
evaluation. During  anaesthesia, all patients were awake and alert with a 
sedation score of 1.  And after treatment for shivering, the sedation score 
was 2. No patients in our study were noticed with a score of 3 or 4.  There 
is no statistical significance between three groups; It was similar to study 
conducted by vander stappen et al in 1996, to evaluate the efficacy of 
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clonidine on post operative shivering and concluded there is no increase in 
post operative sedation.  
 
   In our study, the comparison of shivering score done between three 
groups showed grade -3 as per Wrench grades of shivering. All patients in 
three groups were in the grade-3 shivering; the statistical analysis showed  
no significance between groups.   The comparison of side effects in our 
study; 2 patients in group T with nausea and sedation: 2 patients with 
nausea  alone and others with sedation  noticed: In group C and group N: 
all the 25 patients had sedation. No other side effects noticed.  
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SUMMARY 
 
 A clinical study was undertaken to compare the effect of drugs in 
control of shivering. The effect of nalbuphine, clonidine and tramadol in 
the control of shivering were studied in parturients undergoing caesarean 
section under spinal Anaesthesia. 
 
 The clinical study was conducted in Thanjavur Medical Collage from 
July 2013 to July 2014. ASA Grade I and II patients subjected to elective or 
emergency  caesarean section under spinal anaesthesia who in due course 
of anaesthesia developed shivering were included in the study. Total of 75 
parturients were studied. They were randomly divided into three groups, 
group T (n=25) received 0.5mg/kg of tramadol iv, group  C (n=25) received 
0.5µg/kg of clonidine iv and group N (n= 25) received 0.1mg/kg of 
nalbuphine iv. The attending anaesthesiologist  observed for the cessation 
of shivering and he/she noted the time elapsed from treatment to the time 
shivering stopped. 
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 Statistical analysis revealed significant response with 0.5µg/kg iv 
clonidine when compared with 0.5mg/kg of tramadol and 0.1mg/kg 
nalbuphine. Also clonidine was found to have better control over 
hemodynamics especially at 2mts of post anaestheticshivering and also 
better sedation. 
 
 
 Hence from the above study, it can be concluded that clonidine in a 
dose of 0.5µg/kg iv is better for control of shivering in parturients 
undergoing caesarean section under spinal anasthesia.  
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CONCLUSION 
 
In conclusion all three drugs used in this study namely tramadol 
(0.5mg/kg), nalbuphine (0.1mg / kg) and clonidine (0.5µg/kg) effectively 
treated post spinal anaesthesia shivering. Among them clonidine took lesser 
time to achieve complete cessation of shivering and also maintained better 
hemodynamics throughout the study. Tramadol and nalbuphine were also 
equally effective in controlling post spinal anaesthesia shivering and can be 
used as a safe alternative. 
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                                         ANNEXURE IV 
Proforma 
PROFORMA 
 
 
  
Name : I.P. No. : 
  
Age : Hospital : 
  
Sex : Date : 
 
Type of surgery 
 
 
 
PRE ANAESTHETIC EVALUATION  : 
 
 
 
General physical examination : 
 
 
  
Pulse rate 
  
B.P. 
  
R.R 
  
Weight 
 
SPO2 
ASA  
  
Systemic examination : 
  
C.V.S : 
  
R.S. : 
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STUDY DRUGS 
 
GROUP C - Inj Clonidine 0.5 µg/kg  iv 
 
GROUP N - Inj Nalbuphine 0.1 mg/kg iv 
 
GROUP T - Inj Tramadol 0.5 mg/kg  iv 
 
Time of spinal anaesthesia  : 
Onset of shivering    : 
Grade of shivering    : 
Time to disappearance  of shivering : 
Response rate     : 
Duration of surgery   : 
Duration of spinal anaesthesia  : 
Axillary temperature   : 
Recurrence of shivering   : 
Intraop hemodynamics    
 
Parameter Onset 5mts 10mts 15mts 20mts 25mts 30mts 40mts 50 
mts 
60mts 
PR           
BP           
SPO2           
RR           
   
SEDATION SCORE 
 
SIDE EFFECTS 
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Master Chart 
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List of Statistical formulae used 
 
 
1. Mean =  =  
 
  
2.  SD   
 
 
 
3.   t = Difference of means 
 
              SE of mean 
 
4.   2 =      (O -E) 2 
 
 
 
O – Observed values 
 
 
E – Expected values 
 
 
Anova is a statistical test which analyzes variance. It is helpful in making 
comparison of two or more means which enables a researcher to draw various 
results and predictions about two or more sets of data. Anova test includes one-
way anova, two-way anova or multiple anova depending upon the type and 
arrangement of the data. One-way anova has the following test statistics: 
 
 
Where, 
 
F = Anova Coefficient 
 
MST = Mean sum of squares due to treatment 
 
MSE = Mean sum of squares due to error. 
  
E 
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Formula for MST is given below: 
 
 
 
 
Where, 
 
SST = Sum of squares due to treatment 
 
p = Total number of populations 
 
n = Total number of samples in a population. 
 
Formula for MSE is given below: 
 
 
 
 
Where, 
SSE = Sum of squares due to error 
 
S = Standard deviation of the samples 
 
N = Total number of observations. 
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CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by Dr.J.VASANTHY, Post Graduate in 
Anaesthesia, Department of Anesthesiology,Thanjavur Medical College and 
hospital,Thanjavur and to use my personal clinical data and result of investigation 
for the purpose of analysis and to study the nature of disease. I also give consent 
for further investigations 
 
 
Place : 
Date :       Signature of Participant 
 
 
 
 
 
 


